Trial Profile
A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Adenocarcinoma; Anal cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 29 Sep 2018 Results published in the European Journal of Cancer
- 02 Dec 2016 Results assessing safety and efficacy of afatinib plus standard-dose cetuximab in patients with advanced solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 11 May 2016 Status changed from active, no longer recruiting to completed.